SAN MATEO, Calif., June 21, 2013 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that is developing novel therapeutics for heart failure patients, today announced it has filed its Annual Report on Form 10-K for the year ended December 31, 2012, as well its Quarterly Reports on Form 10-Q for each of the quarters ended September 30, 2012 and March 31, 2013. As a result of these filings, Nile is now current with its obligations to file reports with the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.
SOURCE Nile Therapeutics, Inc.